Seelos Therapeutics Inc. [NASDAQ: SEEL] gained 56.25% or 1.71 points to close at $4.75 with a heavy trading volume of 309461998 shares. The company report on March 5, 2021 that Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder.
-Open-Label Efficacy and Safety Data of Imminently Suicidal Patients Dosed with SLS-002 Expected in the Second Quarter of 2021.
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced the completion of enrollment of patients in Part 1 of its registrational Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).
It opened the trading session at $3.90, the shares rose to $5.89 and dropped to $3.65, the range by which the price of stock traded the whole day. The daily chart for SEEL points out that the company has recorded 633.14% gains over the past six months. However, it is still -1030.95% lower than its most recent low trading price.
If we look at the average trading volume of 3.51M shares, SEEL reached to a volume of 309461998 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Seelos Therapeutics Inc. [SEEL]:
The Benchmark Company have made an estimate for Seelos Therapeutics Inc. shares, keeping their opinion on the stock as Speculative Buy, with their previous recommendation back on November 14, 2019. The new note on the price target was released on May 14, 2019, representing the official price target for Seelos Therapeutics Inc. stock.
The Average True Range (ATR) for Seelos Therapeutics Inc. is set at 0.56 The Price to Book ratio for the last quarter was 95.00, with the Price to Cash per share for the same quarter was set at 0.34.
Trading performance analysis for SEEL stock
Seelos Therapeutics Inc. [SEEL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 82.69. With this latest performance, SEEL shares gained by 33.05% in over the last four-week period, additionally plugging by 633.14% over the last 6 months – not to mention a rise of 705.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SEEL stock in for the last two-week period is set at 73.14, with the RSI for the last a single of trading hit 78.73, and the three-weeks RSI is set at 70.39 for Seelos Therapeutics Inc. [SEEL]. The present Moving Average for the last 50 days of trading for this stock 2.64, while it was recorded at 3.32 for the last single week of trading, and 1.42 for the last 200 days.
Seelos Therapeutics Inc. [SEEL]: A deeper dive into fundamental analysis
Return on Total Capital for SEEL is now -305.30, given the latest momentum, and Return on Invested Capital for the company is -387.52. Return on Equity for this stock declined to -1,489.36, with Return on Assets sitting at -133.62. When it comes to the capital structure of this company, Seelos Therapeutics Inc. [SEEL] has a Total Debt to Total Equity ratio set at 378.07. Additionally, SEEL Total Debt to Total Capital is recorded at 79.08, with Total Debt to Total Assets ending up at 55.58. Long-Term Debt to Equity for the company is recorded at 283.55, with the Long-Term Debt to Total Capital now at 59.31.
Reflecting on the efficiency of the workforce at the company, Seelos Therapeutics Inc. [SEEL] managed to generate an average of -$1,910,100 per employee.Seelos Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.40.
Seelos Therapeutics Inc. [SEEL]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Seelos Therapeutics Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.16/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -68.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SEEL.
An analysis of insider ownership at Seelos Therapeutics Inc. [SEEL]
There are presently around $36 million, or 11.00% of SEEL stock, in the hands of institutional investors. The top three institutional holders of SEEL stocks are: VANGUARD GROUP INC with ownership of 2,799,854, which is approximately 469.67% of the company’s market cap and around 13.38% of the total institutional ownership; UNIPLAN INVESTMENT COUNSEL, INC., holding 1,927,036 shares of the stock with an approximate value of $9.15 million in SEEL stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $3.34 million in SEEL stock with ownership of nearly 18.847% of the company’s market capitalization.
Positions in Seelos Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 19 institutional holders increased their position in Seelos Therapeutics Inc. [NASDAQ:SEEL] by around 3,366,473 shares. Additionally, 16 investors decreased positions by around 851,305 shares, while 7 investors held positions by with 3,280,174 shares. The mentioned changes placed institutional holdings at 7,497,952 shares, according to the latest SEC report filing. SEEL stock had 9 new institutional investments in for a total of 649,416 shares, while 11 institutional investors sold positions of 651,808 shares during the same period.